Ben Greenblum specializes in complex civil litigation, with an emphasis on antitrust and intellectual property disputes. Ben litigates on behalf of corporations and individuals in federal and state courts across the country, and has served as lead defense counsel in several multidistrict litigation and other complex proceedings.
In 2014, Ben was part of the trial team that defended an international pharmaceutical company from a $60 billion antitrust claim alleging a so-called “reverse payment” patent settlement. The case was the first of its kind to go to trial, and to date the only of its kind to go to verdict. The jury’s verdict for the defense was affirmed on appeal. Since then, Ben has represented several pharmaceutical firms in various high stakes antitrust disputes.
Ben also has experience in a range of other substantive areas, including food and drug law, securities law, and claims of unfair competition, fraud and breach of contract. He has represented several companies in contract, licensing and antitrust disputes related to their intellectual property. He has also defended clients in Federal Trade Commission investigations.
Benchmark Litigation has included Ben in their rankings since 2019. He was also selected as a “Rising Star” in the 2014 through 2017 Washington, D.C. editions of Super Lawyers.
A native of Washington, D.C., Ben graduated summa cum laude from the dual degree program of the University of Pennsylvania in 2001, earning both a B.S. from the Wharton School and a B.A. from the College of Arts & Sciences. He then received a J.D. from Columbia Law School in 2006, where he graduated at the top of his class, earning the James Kent Scholar designation every year. While in law school, Ben served on the editorial board of the Columbia Law Review.
Ben joined the firm in 2007 after clerking for the Honorable Dennis Jacobs, then-Chief Judge of the United States Court of Appeals for the Second Circuit. He currently serves as a member of the firm’s Budget Committee.
- Lead defense counsel for pharmaceutical companies in several consolidated “reverse payment” cases pending in the Southern District of New York.
- Defense counsel in several district court proceedings brought by competitors and purchasers alleging monopolization by means of refusal to deal, sham litigation, and improper listings in the FDA’s Orange Book.
- Defense counsel to food manufacturers in antitrust and unfair competition cases alleging price-fixing, anticompetitive distribution restrictions and mislabeling.
- Lead defense counsel for distributor in MDL antitrust proceeding in Eastern District of Virginia concerning alleged antitrust conspiracy.
- Plaintiff counsel in licensing and contract disputes related to first-of-its kind antibody product.
- Defense counsel to European bank in various fraud claims over mortgage-backed securities.
- Defense counsel in proceedings alleging fraud in the structuring of oil and gas investments.
- Plaintiff counsel in breach of contract proceedings over failed development of software.
- Lead defense counsel for multinational energy firm in arbitration proceedings over plant acquisition.
- Defense counsel in cases involving allegations of failure to exercise commercially reasonable efforts in developing pharmaceutical products.